联合磁共振成像与前列腺特异性抗原的筛查路径评估:IP1-PROSTAGRAM研究结果
IP1-PROSTAGRAM是一项前瞻性、基于人群的配对队列研究,纳入408名50-69岁男性,比较13种联合PSA与MRI的筛查路径。标准PSA路径(PSA≥3 ng/ml+系统穿刺)活检转诊率10%、GG≥2癌检出率1.0%;PSA≥1.0 ng/ml联合MRI评分≥4路径检出GG≥2癌2.5%(95%CI 1.3-4.6)且活检转诊率仅7.1%(95%CI 4.9-10.2),作者认为该路径是未来首轮筛查研究中优先评估的策略。
要点
- 标准PSA路径(PSA≥3 ng/ml+系统穿刺)活检转诊率10%,GG≥2癌检出率1.0%。
- PSA≥1.0 ng/ml联合MRI评分≥4路径检出GG≥2癌2.5%(95%CI 1.3-4.6),活检转诊率7.1%(95%CI 4.9-10.2)。
- 仅依赖MRI评分≥3的路径活检率更高,但癌症检出率也高。
核心结论
- 结果凸显了减少过度活检与维持GG≥2癌检出率之间的权衡。
- PSA≥1 ng/ml联合MRI评分≥4的路径维持了GG≥2癌检出,同时减少活检转诊人数,是未来首轮筛查研究中优先评估的策略。
研究设计与样本
- IP1-PROSTAGRAM是一项前瞻性、基于人群的配对队列研究,纳入408名50-69岁男性,于2018年10月10日至2019年5月15日在英国七个初级保健诊所和两个影像中心开展。
- 所有参与者接受PSA检测、MRI(T2加权和扩散)及经直肠超声(B模式和弹性成像)筛查;任一检查筛查阳性即行12针系统穿刺,MRI或超声阳性时额外行图像融合靶向穿刺。
- 预设统计分析比较13种不同路径,包括单用PSA、单用MRI及一系列PSA阈值和MRI评分。
主要发现
- 标准PSA路径(PSA≥3 ng/ml+系统穿刺)活检转诊率10%,GG≥2癌检出率1.0%。
- 单用MRI评分≥3作为活检阈值的路径活检率更高,但癌症检出率高。
- PSA≥1.0 ng/ml联合MRI评分≥4路径检出GG≥2癌2.5%(95%CI 1.3-4.6),活检转诊率7.1%(95%CI 4.9-10.2)。
关键数值与推荐
- 靶向穿刺仅在PROSTAGRAM MRI显示病灶评分为3、4或5时进行。
- 标准PSA路径定义为PSA≥3 ng/ml+系统穿刺。
- 联合路径定义为初始低PSA阈值(≥1.0 ng/ml)和MRI评分≥4。
临床怎么用
- 作者认为PSA≥1.0 ng/ml联合MRI评分≥4路径是未来首轮筛查研究中优先评估的策略。
- 原文未据此给出临床推荐。
局限性
- 结果仅适用于一个筛查轮次,重复筛查轮次的影响未评估。
- 目前缺乏所需的MRI容量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of prostate-specific antigen (PSA) testing to screen for prostate cancer has been fraught with under- and overdiagnosis. Short, noncontrast magnetic resonance imaging (MRI) might detect more grade group ≥2 cancers with similar rates of biopsy. OBJECTIVE: To evaluate strategies that combined PSA and MRI to select men based in the community for a prostate biopsy. DESIGN, SETTING, AND PARTICIPANTS: IP1-PROSTAGRAM was a prospective, population-based, paired cohort study of 408 men aged 50-69 yr conducted at seven UK primary care practice and two imaging centres (from October 10, 2018 to May 15, 2019). INTERVENTION: All participants underwent screening with a PSA test, MRI (T2-weighted and diffusion), and transrectal ultrasound (b-mode and elastography). If any test was screen positive, a systematic 12-core biopsy was performed. Additional image-fusion targeted biopsies were taken if the MRI or ultrasound was positive. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We conducted an analysis, set out in the statistical plan a priori, comparing 13 different pathways including PSA-alone, MRI-alone, and a range of PSA thresholds and MRI scores. The performance of each pathway was evaluated focusing on the trade-offs between biopsy referral rates and detection of grade group ≥2 cancers. A targeted biopsy was performed only where the PROSTAGRAM MRI showed a lesion score of 3, 4, or 5. RESULTS AND LIMITATIONS: The standard PSA pathway (PSA ≥3 ng/ml + systematic biopsy) would lead to 10% of men being referred for a biopsy and a 1.0% detection rate of grade group ≥2 cancers. Pathways that relied on MRI alone set at a threshold score of 3 for a biopsy led to higher biopsy rates, but with benefit of high cancer detection rates. The pathway that combined an initial low PSA threshold (≥1.0 ng/ml) and MRI score ≥4 accurately identified a high rate of grade group ≥2 cancers (2.5%, 95% confidence interval 1.3-4.6) while recommending fewer patients for a biopsy (7.1%, 95% confidence interval 4.9-10.2). The results are pertinent to only one screening round, the impact of repeat screening rounds is not evaluated, and the required MRI capacity is currently lacking. CONCLUSIONS: Our results highlight the trade-off that exists between reducing excessive numbers of biopsies and maintaining grade group ≥2 cancer detection rates. A pathway that combines PSA ≥1 ng/ml and MRI score ≥4 maintains the detection of grade group ≥2 cancers while recommending fewer men for biopsies and would be the preferred strategy to evaluate in future studies at the first screening round. PATIENT SUMMARY: The IP1-PROSTAGRAM study shows that PROSTAGRAM magnetic resonance imaging in men with a prostate-specific antigen level of ≥1.0 ng/ml could be a promising pathway to evaluate in future screening trials.
引用
- Eldred-Evans D, Tam H, Sokhi H, et al. An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study. Eur Urol Oncol. 2023. PMID: 37080821. doi:10.1016/j.euo.2023.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。